• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

    35.01 +0.52 (+1.51%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 1, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,895,528
    Open 34.54
    Bid (Size) 34.68 (5)
    Ask (Size) 35.39 (1)
    Prev. Close 34.49
    Today's Range 34.38 - 35.40
    52wk Range 9.570 - 34.61
    Shares Outstanding 105,736,200
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals
    Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week technical strength and strong price action. 
    Via Benzinga
    Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire

    Performance

    YTD
    +78.2%
    +78.2%
    1 Month
    +36.3%
    +36.3%
    3 Month
    +117.6%
    +117.6%
    6 Month
    +186.8%
    +186.8%
    1 Year
    +80.7%
    +80.7%

    More News

    Read More
    Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Arrowhead Stock Rockets 11% Today – Retail Says $200M Upfront Payment From Novartis Collaboration Is ‘Hell Of A Deal’
    Via Stocktwits
    Earnings Scheduled For August 7, 2025
    Via Benzinga
    Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal
    Via The Motley Fool
    Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Arrowhead Pharma Jumps After Inking A Deal Worth Up To $2.2 Billion
    Via Investor's Business Daily
    Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    This Analyst Says Sarepta Lost Credibility By Exiting Arrowhead At A Loss, But Retail Sees Stock Hitting $30 By Next Week
    Via Stocktwits
    Sarepta Sells Arrowhead Stake To Stretch Its Cash Runway; And One Stock Dives
    Via Investor's Business Daily
    Topics Death
    Sarepta Keeps Retail Traders Bullish As Stock Surges On $100M Milestone Payment To Arrowhead In Genetic Disorder Trial
    Via Stocktwits
    Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Arrowhead (ARWR) Q3 2025 Earnings Call Transcript
    Via The Motley Fool
    Topics Earnings
    Arrowhead (ARWR) Q3 Revenue Drops 41%
    Via The Motley Fool
    Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Reports Mixed Q3 2025 Results with Revenue Beat but Wider-Than-Expected Loss
    Via Chartmill
    Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Sarepta Therapeutics Surges Over 40% In Tuesday Pre-Market: What's Going On?
    Via Benzinga
    FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys
    Via Benzinga
    Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy
    Via Benzinga
    Sarepta Therapeutics' Brutal Week Continues With Bad News Out Of Europe
    Via Investor's Business Daily
    Topics Death
    Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire

    Frequently Asked Questions

    Is Arrowhead Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Arrowhead Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Arrowhead Pharmaceuticals, Inc. - Common Stock trade on?
    Arrowhead Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Arrowhead Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Arrowhead Pharmaceuticals, Inc. - Common Stock is ARWR on the Nasdaq Stock Market
    What is the current price of Arrowhead Pharmaceuticals, Inc. - Common Stock?
    The current price of Arrowhead Pharmaceuticals, Inc. - Common Stock is 35.01
    When was Arrowhead Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Arrowhead Pharmaceuticals, Inc. - Common Stock was at 10/01/25 04:00 PM ET
    What is the market capitalization of Arrowhead Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Arrowhead Pharmaceuticals, Inc. - Common Stock is 3.70B
    How many shares of Arrowhead Pharmaceuticals, Inc. - Common Stock are outstanding?
    Arrowhead Pharmaceuticals, Inc. - Common Stock has 4B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.